Stocks and Investing
Stocks and Investing
Mon, September 23, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Leland Gershell Reiterated (CAPR) at Buy and Held Target at $15 on, Sep 23rd, 2024
Leland Gershell of Oppenheimer, Reiterated "Capricor Therapeutics, Inc." (CAPR) at Buy and Held Target at $15 on, Sep 23rd, 2024.
Leland has made no other calls on CAPR in the last 4 months.
There are 3 other peers that have a rating on CAPR. Out of the 3 peers that are also analyzing CAPR, 0 agree with Leland's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Leland
- Kristen Kluska of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $8 on, Friday, September 20th, 2024
- Jason McCarthy of "Maxim Group" Reiterated at Strong Buy and Held Target at $12 on, Tuesday, September 17th, 2024
- Joseph Pantginis of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $40 on, Tuesday, September 17th, 2024
Contributing Sources